Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prescription savings may look simple on the GoodRx app, but the company鈥檚 disclosures tell a deeper story of PBM economics, subscription growth, and regulatory scrutiny. If you came searching for 鈥淕oodRx SEC filings explained simply鈥� or wondered, 鈥淲here can I find the GoodRx annual report 10-K simplified?鈥�, you鈥檙e in the right place. Stock Titan鈥檚 AI reads each page鈥攚hether a 300-page 10-K or a same-day 8-K鈥攁nd surfaces what matters: PBM concentration risk, monthly active consumer trends, and the real cost of prescription transactions.
Use our dashboard to jump straight into GoodRx quarterly earnings report 10-Q filing summaries, monitor GoodRx insider trading Form 4 transactions, and receive GoodRx Form 4 insider transactions real-time alerts. Our technology converts dense footnotes into plain language, so understanding GoodRx SEC documents with AI feels intuitive, not intimidating. Curious about executive pay? The GoodRx proxy statement executive compensation section is distilled into key figures and policy changes. Need context on sudden announcements? Check the GoodRx 8-K material events explained card for instant clarity.
Every filing type is covered and updated the moment EDGAR posts it鈥�10-Ks, 10-Qs, 8-Ks, DEF 14As, S-8s, even Section 16 reports. Investors rely on our AI-powered summaries to perform GoodRx earnings report filing analysis, trace GoodRx executive stock transactions Form 4, and benchmark telehealth revenue streams without wading through legalese. Whether you鈥檙e tracking margin trends or validating insider purchase signals, Stock Titan equips you with concise insights, real-time data, and direct links to the source documents so you can act decisively.
American Eagle Outfitters (AEO) has filed a Form 3 detailing the initial beneficial ownership of Beth M. Henke, who is identified as the company鈥檚 Executive Vice President & Chief Legal Officer. Henke directly owns 4,635 shares of AEO common stock. She also holds three tranches of restricted stock units (RSUs) that collectively represent 20,285.34 additional shares once vested and converted:
- 11,990.34 RSUs that vest in three equal annual installments beginning one year after the grant date.
- 4,252.42 RSUs that vest 50% on 04/04/2026 and 50% on 04/04/2027.
- 4,042.58 RSUs that vest fully on 03/30/2026.
Each RSU converts into one share of common stock upon vesting. No indirect ownership or additional derivative securities were reported. The filing is an administrative disclosure required under Section 16(a) to record the officer鈥檚 initial equity position.
Spectrum Equity reduces, but still retains a significant position in GoodRx Holdings, Inc. (NASDAQ: GDRX) according to Amendment No. 6 to its Schedule 13D. The filing reflects events through 2 July 2025 and amends the original Schedule 13D first filed in June 2021 and most recently updated in June 2025.
Key ownership data: the five affiliated reporting entities 鈥� Spectrum Equity VII, L.P.; Spectrum Equity Associates VII, L.P.; Spectrum VII Investment Managers鈥� Fund, L.P.; Spectrum VII Co-Investment Fund, L.P.; and SEA VII Management, LLC 鈥� now beneficially own an aggregate 14,905,133 Class A shares, equal to 12.9 % of the outstanding Class A common stock (115,205,298 shares assumed outstanding). The bulk of the holding (14,865,346 shares) resides in Spectrum Equity VII, L.P., with two smaller funds owning 25,445 and 14,342 shares, respectively.
Recent transactions:
- Pro-rata distribution: On 2 July 2025, Spectrum Equity VII, L.P. distributed 3,989,323 Class A shares of GoodRx to its limited partners for no consideration (the 鈥淛uly 2025 Distribution鈥�).
- Follow-on sales: After the distribution, Spectrum VII Co-Investment Fund, L.P. and Spectrum VII Investment Managers鈥� Fund, L.P. sold a combined 10,677 Class A shares in the open market, generating net proceeds of $50,606.46.
Control structure: SEA VII Management, LLC is the general partner of the other Spectrum vehicles and, together with eight named individuals, shares voting and dispositive power over the reported shares. Each individual disclaims beneficial ownership.
Implications for investors: The 3.99 million-share distribution lowers Spectrum Equity鈥檚 direct stake while increasing GoodRx鈥檚 public float, potentially improving liquidity but signalling a partial exit by an early sponsor. Despite the reduction, Spectrum Equity remains a >10 % beneficial owner, so it continues to be a significant shareholder with aligned interests, although further sell-downs remain possible. No other material changes, litigation matters or additional share transactions were reported in the past 60 days.
Form 4 overview: Kratos Defense & Security Solutions (KTOS) President of the KTT Division, Stacey G. Rock, reported two open-market sales of the company鈥檚 common stock executed on 07/01/2025 under a previously adopted Rule 10b5-1 trading plan.
- Shares sold: 3,456 at a weighted-average price of $45.2912 and 544 at $46.28, totaling 4,000 shares.
- Proceeds: Approximately $180,000 based on reported averages.
- Post-sale holdings: 46,243 shares, including 1,723 shares from the ESPP and ~6,814 shares held through the 401(k) plan.
- Reporting person status: Officer鈥擯resident, KTT Division.
No derivative transactions were reported. The filing was signed on 07/03/2025.
GoodRx Holdings, Inc. (GDRX) filed a Form 144 indicating the intent to sell 6,828 Class A shares through Merrill Lynch on or after 07/03/2025. The proposed sale represents approximately 0.0068% of the 100.3 million shares outstanding and has an estimated aggregate market value of $32,159.88. The shares were originally acquired in a private placement on 10/15/2015. Filers related to Spectrum VII funds sold a total of 10,677 Class A shares over the past three months for gross proceeds of $43,706.29. No other financial metrics, earnings data, or corporate developments are disclosed in this notice.
GoodRx Holdings, Inc. (GDRX) 鈥� Form 144 filing overview
The notice discloses a proposed sale of 3,849 Class A shares of GoodRx, to be executed through Merrill Lynch on or about 07/03/2025. Based on an aggregate market value of $18,128.79, the implied share price is roughly $4.71. The seller acquired the shares on 10/15/2015 via a private placement and intends to receive cash proceeds. GoodRx reports 100,300,165 Class A shares outstanding, so the planned sale represents only 0.0038 % of the float.
The filing also lists sales made during the past 3 months by related investment vehicles:
- Spectrum VII Co-Investment Fund, LP sold 3,849 shares on 06/06/2025 for $15,755.88.
- Spectrum VII Investment Managers鈥� Fund, LP sold 6,828 shares on 06/06/2025 for $27,950.41.
No material adverse information is acknowledged by the filer, and the transaction follows Rule 144 requirements, indicating procedural compliance rather than a strategic corporate event. The modest size suggests limited market impact, though investors often monitor insider activity for sentiment signals.
FAQ
What is the current stock price of Goodrx Holdings (GDRX)?
What is the market cap of Goodrx Holdings (GDRX)?
What is the core business of GoodRx Holdings, Inc.?
How does GoodRx generate its revenue?
What services does GoodRx offer to consumers?
How does the GoodRx for Benefits solution work?
In what ways does GoodRx facilitate prescription affordability?
How does GoodRx support healthcare professionals?
What differentiates GoodRx from its competitors?
What challenges does GoodRx face in the current healthcare environment?
